50 research outputs found
RECENT DEVELOPMENTS OF THE EU FARMLAND MARKETS: NATIONAL VARIABLES AND COMPARATIVE EFFECTS OF THE CAP REFORM IN SELECTED COUNTRIES
The present paper consists of two main parts. The first one gives a picture of the more recent development of the farmland market in selected EC countries since 1985/86. Two main indicators are used to make relatively comparable the observed trends concerning: i) land mobility, ii) farmland values. The second one tries to evaluate the effects of the CAP reform and the influence of national variables overtime, taking into account the following indicators: i) mobility (on land transfers; on tenancy), ii) income (for agricultural or forest use), iii) farmland values (in the plain; in the hill/mountain areas). Considerations on land market complexity and segmentation are finally included, with justification on the empirical approach adopted in the paper.
Testing a low molecular mass fraction of a mushroom (Lentinus edodes) extract formulated as an oral rinse in a cohort of volunteers
Central venous access devices in pediatric malignancies: A position paper of Italian association of pediatric hematology and oncology
Effect of Lactoferrin on Clinical Outcomes of Hospitalized Patients with COVID-19: The LAC Randomized Clinical Trial
As lactoferrin is a nutritional supplement with proven antiviral and immunomodulatory abilities, it may be used to improve the clinical course of COVID-19. The clinical efficacy and safety of bovine lactoferrin were evaluated in the LAC randomized double-blind placebo-controlled trial. A total of 218 hospitalized adult patients with moderate-to-severe COVID-19 were randomized to receive 800 mg/die oral bovine lactoferrin (n = 113) or placebo (n = 105), both given in combination with standard COVID-19 therapy. No differences in lactoferrin vs. placebo were observed in the primary outcomes: the proportion of death or intensive care unit admission (risk ratio of 1.06 (95% CI 0.63–1.79)) or proportion of discharge or National Early Warning Score 2 (NEWS2) ≤ 2 within 14 days from enrollment (RR of 0.85 (95% CI 0.70–1.04)). Lactoferrin showed an excellent safety and tolerability profile. Even though bovine lactoferrin is safe and tolerable, our results do not support its use in hospitalized patients with moderate-to-severe COVID-19